Skip to main content
. 2021 Sep 30;74(5):2580–2594. doi: 10.1002/hep.31992

FIG. 4.

FIG. 4

(A) TTP and OS from the time of listing among the SBRT, TACE, and HIFU groups. (B) Overall and recurrence‐free survival after transplant among the SBRT, TACE, and HIFU groups.